Related Experiment Video

Updated: May 5, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients

Tatsuo Kanda1, Osamu Yokosuka, Masao Omata

  • 1Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Japan.

Chinese Medical Journal
|November 30, 2013
PubMed

Insights

New direct antiviral agents (DAAs) offer improved hepatitis C virus (HCV) treatment, but some patients remain difficult to treat. Research reviews DAAs and identifies patient groups needing further therapeutic strategies.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Direct antiviral agents (DAAs) represent a significant advancement in treating hepatitis C virus (HCV) infection.
  • Previous treatments often had lower sustained virological response (SVR) rates and significant side effects.

Purpose of the Study:

  • To review current research on DAAs for HCV treatment.
  • To specifically address treatment challenges in "difficult-to-treat" HCV populations.

Main Methods:

  • Literature search of PubMed and Google Scholar databases up to July 2013.
  • Review of published clinical trials and real-world data on DAAs for HCV.

Main Results:

  • DAAs, including telaprevir and boceprevir, achieve higher SVR rates.
  • Certain patient groups, such as those with advanced fibrosis, cirrhosis, co-infections (HIV), elderly, and children, remain challenging to treat effectively.
  • Despite advancements, a subset of patients will still require tailored therapeutic approaches.

Conclusions:

  • Even with potent DAAs, some HCV patients remain difficult to treat.
  • Interferon-sparing regimens may offer enhanced efficacy for these challenging cases, though further clinical trial evidence is needed.
Abstract

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K